News Viridian’s Lumvoa Wins FDA Approval, Taking Direct Aim at Amgen’s Tepezza in Thyroid Eye Disease pharminent June 29, 2026
Clinical Data BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit pharminent June 29, 2026
Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe pharminent June 29, 2026
Regulatory Replimune gets early August decision date for twice-rejected melanoma drug pharminent June 26, 2026
Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026
M&A / Deals Ionis grants Recordati rights to zilganersen for Alexander disease pharminent June 26, 2026
Regulatory Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use pharminent June 25, 2026
Regulatory FDA’s uniQure, REGENXBIO reversals could bolster other near-term rare disease applications pharminent June 25, 2026
Manufacturing SK pharmteco Launches SKyvec Viral Vector Platform for Gene Therapy pharminent June 24, 2026
M&A / Deals URA and Lilly join forces to harmonise drug-wearable obesity care pharminent June 24, 2026
Clinical Data Pfizer drug acquired in Seagen deal disappoints in lung cancer study pharminent June 23, 2026
Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026
Commercial The first 14 days: How specialty programs set patients up for success pharminent June 22, 2026
Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline pharminent June 19, 2026
Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026
